Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Plunkett Research, Ltd.
|
$99.00
|
|
Provider: Plunkett Research, Ltd.
|
$99.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Novo Nordisk A/S Concludes Share Repurchase Program
Novo Nordisk A/S announced that it has concluded a share repurchase program initiated on August 9, 2012. Under the program the Company has repurchased B shares for an amount of DKK 2.0 billion in the period from August 9, 2012 to October 29, 2012. The Company owns a total of 17,189,296 treasury shares, corresponding to 3.1% of the share capital. The total amount of shares in the Company is 560,000,000 including treasury shares.
Latest Developments for Novo Nordisk A/S
- Novo Nordisk A/S Reports 8% Weight Loss in Phase 3a Obesity Trial with Liraglutide 3 mg
- Novo Nordisk A/S Reports Positive Results from First Phase 3 Trial with Long-Acting Factor IX for Treatment of Haemophilia B
- Novo Nordisk A/S Specifies FY 2013 Sales Growth Guidance, Confirms FY 2013 Operating Profit Guidance and Lowers FY 2013 Net Income Guidance
- Novo Nordisk A/S Concludes Share Repurchase Program
Latest Key Developments in Pharmaceuticals
- Valeant Pharmaceuticals International Inc Near Deal To Acquire Bausch & Lomb From Warburg Pincus LLC-Reuters
- Valeant Pharmaceuticals International Inc Near Deal To Acquire Bausch & Lomb-Reuters
- Astec LifeSciences Ltd Recommends Dividend; Announces Appointment Of Statutory Auditors
- J B Chemicals and Pharmaceuticals Ltd Recommends Dividend
- Share this
- Link this
- Digg this
Follow Reuters